Sign Up

Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity

DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement (the "Credit Agreement") consisting of a $300 million term loan facility and a $100 million revolving credit facility on July 31, 2025. The new Credit Agreement will mature on July 31, 2030.

Among the many enhancements, the new Credit Agreement provides for additional liquidity through an increase in the revolving credit facility from $40 million under the Company's previous credit facilities under the Credit and Guaranty Agreement, dated December 6, 2019, as amended (the "2019 Credit Agreement") to $100 million. The current applicable interest margin was reduced 75 basis points compared to the 2019 Credit Agreement generating more than $2 million of annual interest expense savings. Finally, the annual amortization on the term loan was lowered from 10 percent to 5 percent per year for the term of the loan.

"The new Credit Agreement lowers the interest rate on our debt and increases our liquidity, reflecting the significant progress over the past two years to increase our profitability, reduce debt, and enhance cash flow," said Rob Claypoole, Bioventus President and Chief Executive Officer. "This is expected to further increase our financial flexibility and enable greater optionality for capital deployment moving forward."

The proceeds resulting from the Credit Agreement were used to repay the outstanding loan balance of $333 million under the 2019 Credit Agreement. The Company repaid its obligations under the 2019 Credit Agreement using $30 million drawn on the new ...